Skip to main content
PMC home page
Neurology and Therapy logoLink to Neurology and Therapy
. 2024 Aug 6;13(5):1505–1506. doi: 10.1007/s40120-024-00648-z

Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Piero Barbanti 1,2,✉, Gabriella Egeo 1, Stefania Proietti 3,24, Florindo d’Onofrio 4, Cinzia Aurilia 1, Cinzia Finocchi 5, Laura Di Clemente 6, Maurizio Zucco 6, Alberto Doretti 7, Stefano Messina 7, Massimo Autunno 8, Angelo Ranieri 9, Antonio Carnevale 10, Bruno Colombo 11, Massimo Filippi 11, Miriam Tasillo 12, Steno Rinalduzzi 12, Pietro Querzani 13, Giuliano Sette 14, Lorenzo Forino 4, Francesco Zoroddu 15, Micaela Robotti 16, Alessandro Valenza 17, Cecilia Camarda 18, Laura Borrello 19, Marco Aguggia 20, Giovanna Viticchi 21, Carlo Tomino 22, Giulia Fiorentini 2, Bianca Orlando 1, Stefano Bonassi 23,24, Paola Torelli 25; for the Italian Migraine Registry study group
PMCID: PMC11393228  PMID: 39106033

Correction to: Neurol Ther (2024) 13:611–624 10.1007/s40120-024-00591-z

In Fig. 2d of this article the values of HIT-6 at week 12 for CM and HFEM were swapped. The correct values are as follows and the figure should have appeared as shown below.

HIT-6: week 12 HFEM corresponds to − 18.1

HIT-6: week 12 CM corresponds to − 22.5graphic file with name 40120_2024_648_Figa_HTML.jpg

Fig. 2 d Headache Impact Test-6 (HIT-6) score from baseline to week 48 in patients affected by high-frequency episodic migraine (HFEM, n = 49) or chronic migraine (CM, n = 81)

The original article has been corrected.

Articles from Neurology and Therapy are provided here courtesy of Springer

RESOURCES